From the publishers of JADPRO

MPN Resource Center

Advertisement

Improved survival of patients with myelofibrosis in the last decade: Single-center experience

Last Updated: Wednesday, February 9, 2022

Among 844 patients newly diagnosed with myelofibrosis, median survival in the past decade improved from 48 months to 63 months (P < .001; HR, 0.78 [95% CI, 0.64-0.95]), according to data from a single-center, retrospective study of patients treated from 2000-2010 (n = 373) and 2011-2020 (n = 471). Patients exposed to JAK inhibitor ruxolitinib (n = 532) also had a superior median overall survival of 84 months (95% CI, 70-94 months).

Cancer
Advertisement
News & Literature Highlights

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia

Leukemia

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study

Advertisement
Advertisement